Here are Antti’s comments on how Herantis successfully executed a directed share issue 
Herantis announced late on Wednesday that it has successfully completed a EUR 4.2 million directed share issue. The funding will be used to prepare for the Phase II study of the HER-096 drug candidate and, according to the company, it supports ongoing partnership negotiations. The bridge financing provides the company with room to maneuver at a time when biotechnology stocks have been under pressure in the market. We will update the information regarding the issue in our forecasts by the time of the financial statement report at the latest.